Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.


Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
06 2019
Historique:
received: 30 05 2018
revised: 08 10 2018
accepted: 21 03 2019
pubmed: 31 3 2019
medline: 9 4 2020
entrez: 31 3 2019
Statut: ppublish

Résumé

Besides the detection of somatic receptor tyrosine kinases (RTK) mutations in tumor samples, the current challenge is to interpret their biological relevance to give patients effective targeted treatment. By high-throughput sequencing of the 58 RTK exons of healthy tissues, colorectal tumors, and hepatic metastases from 30 patients, 38 different somatic mutations in RTKs were identified. The mutations in the kinase domains and present in both tumors and metastases were reconstituted to perform an unbiased functional study. Among eight variants found in seven RTKs (EPHA4-Met726Ile, EPHB2-Val621Ile, ERBB4-Thr731Met, FGFR4-Ala585Thr, VEGFR3-Leu1014Phe, KIT-Pro875Leu, TRKB-Leu584Val, and NTRK2-Lys618Thr), none displayed significantly increased tyrosine kinase activity. Consistently, none of them induced transformation of NIH3T3 fibroblasts. On the contrary, two RTK variants (FGFR4-Ala585Thr and FLT4-Leu1014Phe) caused drastic inhibition of their kinase activity. These findings indicate that these RTK variants are not suitable targets and highlight the importance of functional studies to validate RTK mutations as potential therapeutic targets.

Identifiants

pubmed: 30926633
pii: 1535-7163.MCT-18-0582
doi: 10.1158/1535-7163.MCT-18-0582
doi:

Substances chimiques

Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1148

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Leslie Duplaquet (L)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

Martin Figeac (M)

Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, Lille, France.

Frédéric Leprêtre (F)

Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, Lille, France.

Charline Frandemiche (C)

TCBN - Tumorothèque Caen Basse-Normandie, Caen, France.
Réseau Régional de Cancérologie, OncoBasseNormandie, Caen, France.

Céline Villenet (C)

Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, Lille, France.

Shéhérazade Sebda (S)

Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, Lille, France.

Nasrin Sarafan-Vasseur (N)

Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.

Mélanie Bénozène (M)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

Audrey Vinchent (A)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

Gautier Goormachtigh (G)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

Laurence Wicquart (L)

Tumorothèque du C2RC de Lille, Lille, France.

Nathalie Rousseau (N)

TCBN - Tumorothèque Caen Basse-Normandie, Caen, France.

Ludivine Beaussire (L)

Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.

Stéphanie Truant (S)

Department of Digestive Surgery and Transplantation, CHU Lille, Univ Lille, Lille Cedex, France.

Pierre Michel (P)

Department of Hepato-Gastroenterology, Rouen University Hospital, Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen, France.

Jean-Christophe Sabourin (JC)

Department of Pathology, Normandy University, INSERM 1245, Rouen University Hospital, Rouen, France.

Françoise Galateau-Sallé (F)

Department of Pathology, MESOPATH-MESOBANK, Centre Léon Bérard, Lyon, France.

Marie-Christine Copin (MC)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.
Tumorothèque du C2RC de Lille, Lille, France.

Gérard Zalcman (G)

Thoracic Oncology Department, CIC1425/CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Paris, France.

Yvan De Launoit (Y)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

Véronique Fafeur (V)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France.

David Tulasne (D)

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T, Lille, France. david.tulasne@ibl.cnrs.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH